Borregaard
12.3.2021 16:39:05 CET | Globenewswire | Press release
12.03.2021: Borregaard ASA ("Borregaard", OSE ticker: BRG)
Reference is made to the stock exchange notice of 19 February 2021 where Borregaard announced the intent to repurchase up to 250,000 of its outstanding common stock.
Borregaard has in the period from 10 March up to and including 12 March in total purchased 40,000 own shares through broker at an average price of NOK 171.52 per share.
By these transactions, Borregaard has completed its share repurchase programme by repurchasing 250,000 shares of its outstanding common stock.
Following the completion of the above transactions, Borregaard owns a total of 457,196 of own shares, corresponding to 0.46% of Borregaard’s share capital.
Please refer to appendix for further details. The appendices can also be viewed on www.newsweb.no.
Contact:
Lotte Kvinlaug, Investor Relations Officer, +47 922 86 909
This information is subject to the disclosure requirements pursuant to Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 Article 2 section 3.
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ISS World Services A/S2.7.2026 07:04:00 CEST | Press release
ISS extends and expands partnership with public healthcare provider in Southern Europe
Insta Group2.7.2026 07:03:20 CEST | Press release
Insta and CHAOS Industries Partner to Counter Rising Aerial Threats in Europe
Promon2.7.2026 07:00:00 CEST | Press release
LexisNexis Risk Solutions and Promon Align to Strengthen Mobile Fraud Prevention
Sodexo SA2.7.2026 07:00:00 CEST | Press release
Q3 Fiscal 2026 revenues above expectations; focus on execution
Novartis Pharma AG2.7.2026 07:00:00 CEST | Press release
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
